Philip A Routledge
Overview
Explore the profile of Philip A Routledge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deslandes P, Bracchi R, Jones K, Haines K, Carey E, Adams A, et al.
Br J Clin Pharmacol
. 2022 Mar;
88(8):3829-3836.
PMID: 35322450
Aims: This study aimed to assess the impact of a National Reporting Indicator (NRI) on rates of reporting of suspected adverse drug reactions using the Yellow Card scheme following the...
2.
Haines K, Bracchi R, Lang R, Samuels K, Routledge P
Br J Clin Pharmacol
. 2021 Mar;
87(10):3961-3970.
PMID: 33713469
Aims: To review the medicines optimisation activities of the All Wales Medicines Strategy Group (AWMSG), a committee established in 2002 to advise the Welsh Government on "all matters related to...
3.
Bracchi R, Tseliou F, Copeland L, Routledge P, Thomas A, Woods F, et al.
Br J Clin Pharmacol
. 2021 Jan;
87(8):3344-3348.
PMID: 33386761
We used the HealthWise Wales (HWW) platform to explore public knowledge about the UK Yellow Card scheme (YCS), the spontaneous reporting scheme for suspected adverse drug reactions (ADRs) and whether...
4.
Cox A, Wilkins S, Routledge P
Int J Pharm Pract
. 2020 Nov;
28(6):549-551.
PMID: 33156575
No abstract available.
5.
Cox A, Routledge P, Wilkins S
Int J Pharm Pract
. 2019 Nov;
27(6):477-478.
PMID: 31696581
No abstract available.
6.
Keeping S, Deslandes P, Haines K, Routledge P
Pharmacoecon Open
. 2019 Jan;
3(3):343-350.
PMID: 30656545
Objectives: The All Wales Medicines Strategy Group (AWMSG) appraises the clinical and cost effectiveness of new medicines being considered for National Health Service (NHS) prescribing in Wales (UK). The aim...
7.
Varnava A, Bracchi R, Samuels K, Hughes D, Routledge P
Pharmacoeconomics
. 2018 Mar;
36(5):613-624.
PMID: 29520603
Background: The All Wales Medicines Strategy Group (AWMSG) develops prescribing advice and is responsible for appraising new medicines for use in Wales. In this article, we examine the medicines appraisal...
8.
Donnelly K, Bracchi R, Hewitt J, Routledge P, Carter B
PLoS One
. 2017 Apr;
12(4):e0174730.
PMID: 28448593
Background: Hip fractures in the older person lead to an increased risk of mortality, poorer quality of life and increased morbidity. Benzodiazepine (BNZ) use is associated with increased hip fracture...
9.
Routledge P
Br J Clin Pharmacol
. 2012 Jun;
74(4):676-84.
PMID: 22738396
The challenge to achieve safe prescribing merits the adjective 'titanic'. The organisational and human errors leading to poor prescribing (e.g. underprescribing, overprescribing, misprescribing or medication errors) have parallels in the...
10.